|
| Title |
Pub. Date |
Int. Class |
App. Num |
Applicant |
| 51. |
(WO 2008/021368) COMPOSITIONS AND METHODS FOR NEUROPROTECTION
|
21.02.2008
|
A61K 31/366
|
PCT/US2007/018001
|
THE JOHNS HOPKINS UNIVERSITY
|
| |
Disclosed herein are neuroprotective compounds. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of neurodegenerative conditions are provided.
|
| |
|
| 52. |
(WO 2008/021302) AUTOMATED SYSTEM FOR FORMULATING RADIOPHARMACEUTICALS
|
21.02.2008
|
G01N 33/53
|
PCT/US2007/017890
|
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
|
| |
The present invention provides automated systems for the purification of radioisotopes, the formulation of radiopharmaceuticals or both. In preferred embodiments the radioisotopes are produced by a generator. In further preferred embodiments the automated systems comprise replaceable cassettes for easy replacement of the system's networks of tubing. Also provided are replaceable cassettes and kits for use with the automated systems of the invention. The invention further provides methods of using an automated system to purify radioisotopes, formulate radiopharmaceuticals or to do both in series.
|
| |
|
| 53. |
(WO 2008/021288) CONSENSUS CODING SEQUENCES OF HUMAN BREAST AND COLORECTAL CANCERS
|
21.02.2008
|
C12Q 1/68
|
PCT/US2007/017866
|
JOHNS HOPKINS UNIVERSITY
|
| |
Analysis of 13,023 genes in 11 breast and 11 colorectal cancers revealed that individual tumors accumulate an average of ~90 mutant genes but that only a subset of these contribute to the neoplastic process. Using stringent criteria to delineate this subset, we identified 189 genes (average of 11 per tumor) that were mutated at significant frequency. The vast majority of these genes were not known to be genetically altered in tumors and are predicted to affect a wide range of cellular functions, including transcription, adhesion, and invasion. These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention and monitoring.
|
| |
|
| 54. |
(WO 2008/021242) FLUOROTAXOID-FATTY ACID CONJUGATES AND PHARMACEUTICAL COMPOSITIONS THEREOF
|
21.02.2008
|
A61K 31/337
|
PCT/US2007/017806
|
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
|
| |
The invention relates to fluorotaxoid-fatty acid conjugates and pharmaceutical compositions thereof. The conjugates have the following formula:
|
| |
|
| 55. |
(WO 2008/021223) SYSTEM, METHOD, AND DEVICE FOR THE EXPRESSION OR REPRESSION OF PROTEINS
|
21.02.2008
|
C12N 15/82
|
PCT/US2007/017774
|
UNIVERSITY OF GENEVA
|
| |
This invention relates to systems, methods, and devices for inducing and/or repressing the expression of proteins. More particularly, the invention relates to systems, methods, and devices for inducing and/or repressing the expression of proteins in plastids. An exemplary embodiment involves the regulation of the expression of proteins involved in hydrogen production to stimulate the production of hydrogen gas using the methods, systems, and devices described herein.
|
| |
|
| 56. |
(WO 2008/021202) CAPILLARY-BASED CELL AND TISSUE ACQUISITION SYSTEM (CTAS)
|
21.02.2008
|
G02B 21/24
|
PCT/US2007/017742
|
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
|
| |
The present invention relates to a capillary-based cell and tissue acquisition system that integrates the capillary approach with a microscope manipulator to collect and sort cells of interest. Cells of interest are determined by using a laser beam focus to identify the initial contact between the capillary and the cells.
|
| |
|
| 57. |
(WO 2008/021194) ADSORBENT COMPOSITION FOR DESULFURING A FLUID, METHOD AND APPARATUS FOR ITS USE
|
21.02.2008
|
B01D 53/02
|
PCT/US2007/017729
|
THE UNIVERSITY OF HOUSTON SYSTEM
|
| |
An adsorbent compostion for desulfurizing a fluid comprising: at least one compound of a class of porous metal organic compounds of the general formula MOADA, where M is a tetravalent metal or a mixture of tetravalent metals, 0 is an oxygen atom, and ADA is a dianion of a dicarboxylic acid (H2ADA), where the compounds selectively and reversibly adsorb sulfur-containing components in the fluid. Method and apparatus for the use of this adsorbent composition.
|
| |
|
| 58. |
(WO 2008/021193) GUANOSINE RICH OLIGONUCLEOTIDES AND METHODS OF INDUCING APOPTOSIS IN TUMOR CELLS
|
21.02.2008
|
C07H 21/00
|
PCT/US2007/017727
|
UNIVERSITY OF DELAWARE
|
| |
Presently described is a guanosine-rich polynucleotide molecule with therapeutic utility for treating or preventing the growth of cancerous cells. In addition, a method of retarding cell cycle progression and inducing apoptosis in tumor cells using synthetic oligonucleotides is also described.
|
| |
|
| 59. |
(WO 2008/021191) PIEZOELECTRIC COMPOSITIONS
|
21.02.2008
|
H03H 9/58
|
PCT/US2007/017725
|
THE JOHNS HOPKINS UNIVERSITY
|
| |
Piezoelectric compositions are provided wherein mechanical and piezoelectric properties can be separately modulated. Preferred compositions include resin blends that comprise: (a) a piezoelectrically active polymer and (b) a matrix polymer, methods of making, and use of such resin blends. Advantages of preferred resin blends of the invention can include high piezoelectricity, mechanical strength and flexibility, convenient fabrication process, and high sensitivity at high temperatures.
|
| |
|
| 60. |
(WO 2008/021189) CONTROLLING ACCUMULATION OF SELECT ADSORBERS ON A PIEZOELECTRIC CANTILEVER SENSOR
|
21.02.2008
|
H01L 41/04
|
PCT/US2007/017723
|
DREXEL UNIVERSITY
|
| |
The techniques described herein are directed to removing material that has attached to or preventing material from attaching to the surface of a piezoelectric cantilever. The material can be a target material, other, non-target, material that may be weakly bound or attached to the cantilever sensor, or the material may be a combination thereof. Accordingly, the cantilever sensor can be reused, in situ, without degraded detection performance of the cantilever sensor. The techniques may also be utilized to remove all material that has attached to a surface of the cantilever sensor which provides means for reusing the cantilever sensor.
|
| |
|
| 61. |
(WO 2008/021187) FLOW CELLS FOR PEIZOELECTRIC CANTILEVER SENSORS
|
21.02.2008
|
G01N 11/04
|
PCT/US2007/017721
|
DREXEL UNIVERSITY
|
| |
Flow cells configured for piezoelectric millimeter-sized cantilever sensors provide direct, sensitive detection of analytes in fluid media. The flow cells comprise a flow inlet and a flow outlet positioned to cause sample flow past a sensing surface of the cantilever sensor. The flow cell is configured for millimeter-sized cantilever sensors. The geometry of the flow cell influences the sample flow and thus the interaction of the flow with the cantilever sensor.
|
| |
|
| 62. |
(WO 2008/021168) RAPID-THROUGHPUT TELEOST REGENERATION ASSAY
|
21.02.2008
|
A01N 1/00
|
PCT/US2007/017697
|
THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY
|
| |
The present invention provides a method of simultaneously screening at least two candidate agents for an activity affecting regeneration of an embryonic teleost. According to this method, for each agent, a fin of the embryonic teleost is amputated. Next, the amputated teleost is incubated with the candidate agent for a specified period of time. After this period of time, the amputated teloeost is imaged. This image is compared to an image of an amputated teleost that was incubated for the specified period of time in the absence of the candidate agent. When comparing the images, a change in morphology of the amputated fin of the embryonic teleost incubated in the presence of the candidate agent compared to the amputated fin of the embryonic ...
|
| |
|
| 63. |
(WO 2008/021163) KITS AND METHODS FOR DETERMINING RISK FOR PRIMARY LIVER CANCER
|
21.02.2008
|
G01N 33/574
|
PCT/US2007/017690
|
SAINT LOUIS UNIVERSITY
|
| |
Methods and kits for diagnosing hepatocellular carcinoma are disclosed. The methods comprise detecting in a serum sample from a subject the quantity of at least one serum protein which is upregulated in patients with hepatocellular carcinoma. Kits of the present teachings include a capture antibody directed against a first epitope of a serum protein which is upregulated in patients with hepatocellular carcinoma, a detection antibody against a second epitope of the protein, and a labeled secondary protein directed against the detection antibody. The capture antibody can be immobilized on a solid support, such as a multiwell plate or a plastic bead.
|
| |
|
| 64. |
(WO 2008/021160) REGULATION OF LITAF MODULATED CYTOKINE PRODUCTION BY A NOVEL P53 SHORT PEPTIDE
|
21.02.2008
|
C07K 14/47
|
PCT/US2007/017687
|
TRUSTEES OF BOSTON UNIVERSITY
|
| |
The present invention relates to a novel isolated and purified peptide of the sequence KQSQHMT [SEQ ID NO: 1], nucleic acid sequences encoding said peptide sequence and capable of expressing said sequence as an exogenous protein in a target cell; as well as methods for the reduction or inhibition of LITAF activity by transfecting the peptide KQSQHMT [SEQ ID NO: 1] or a nucleic acid capable of expressing said peptide, into a target cell. The present invention also relates to the use of the novel peptide (and corresponding nucleotide sequences) of the present invention for the regulation of cytokine expression in target cells. The present invention also relates to the use of the novel peptide (and corresponding nucleotide sequences) of the pr...
|
| |
|
| 65. |
(WO 2008/021144) MEMS COMB DRIVE ACTUATORS AND METHOD OF MANUFACTURE
|
21.02.2008
|
H02N 1/00
|
PCT/US2007/017649
|
THE ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA acting for and on behalf of ARIZONA STATE UNIVERSITY
|
| |
A micro electromechanical actuator 130 as described herein comprises a support layer 101 and at least one movable comb 110 moun resiliently on the support layer. Each movable comb 110 has a plurality of substantially parallel movable fingers. These parallel fing pass through channels 104 that are fixed with respect to the support layer. An AC and/or DC electrical potential difference can be applied between the channels 104 and the movable fingers 110. Electrostatic forces resulting from this potential difference are capab of moving the fixed fingers through a range of motion. Over at least a portion of this range of motion, some of the movable fingers extend beyond the fixed channels. In designing such a MEMS actuator, the lengths of the fi...
|
| |
|
| 66. |
(WO 2008/021141) RE-ENGINEERING BACTERIA FOR ETHANOL PRODUCTION
|
21.02.2008
|
C12N 1/21
|
PCT/US2007/017646
|
THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
|
| |
The invention provides recombinant bacteria, which comprise a full complement of heterologous ethanol production genes. Expression of the full complement of heterologous ethanol production genes causes the recombinant bacteria to produce ethanol as the primary fermentation product when grown in mineral salts medium, without the addition of complex nutrients. Methods for producing the recombinant bacteria and methods for producing ethanol using the recombinant bacteria are also disclosed.
|
| |
|
| 67. |
(WO 2008/021092) TRYPANOSOME MICROSOME SYSTEM AND USES THEREOF
|
21.02.2008
|
A61K 39/00
|
PCT/US2007/017555
|
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
|
| |
The present invention provides cell free preparations of protozoan microsomes, wherein the cell free preparation of protozoan microsomes demonstrate the ability to translocate a protozoan polypeptide into the microsome, methods of preparing cell free preparations of protozoan microsomes, and methods of using cell free preparations of protozoan microsomes.
|
| |
|
| 68. |
(WO 2008/021088) SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES
|
21.02.2008
|
A61K 38/00
|
PCT/US2007/017551
|
THE REGENTS OF THE UNIVERSITY OF CALIFORNINA
|
| |
This invention pertains to the surprising discovery that salicylanilides, e.g., niclosamide and/or niclosamide analogues when orally administered in conjunction with a peptide pharmaceutical (e.g., a class A amphipathic helical peptide as described herein) significantly increases the bioavailability of that peptide. Methods of peptide delivery using such 'delivery agents' and pharmaceutical formulations are provided.
|
| |
|
| 69. |
(WO 2008/021073) NANOHEATER ELEMENTS, SYSTEMS AND METHODS OF USE THEREOF
|
21.02.2008
|
H05B 3/10
|
PCT/US2007/017524
|
UNIVERSITY OF MASSACHUSETTS
|
| |
The present invention provides devices and methods for making nano structures such a nanoheater. In one embodiment, the nanoheater element comprises a first reactive member and interlayer disposed in communication with at least a portion thereof. Preferably, contact between the first and second reactive members of the nanoheater element can yield at least one exothermic reaction. A nanoheater device of the invention can optionally comprise a substrate on which the first reactive member is positioned in combination with other components. The invention also provides a nanoheater system comprising a plurality of nanoheater elements. Exemplary nanoheater elements and systems can be used to perform a method of the invention in which heat is prod...
|
| |
|
| 70. |
(WO 2008/021054) METHOD FOR THE PREPARATION OF ORGANIC ACIDS VIA OXIDIZATION USING NITRIC ACID
|
21.02.2008
|
C07C 51/27
|
PCT/US2007/017493
|
THE UNIVERSITY OF MONTANA
|
| |
A controlled nitric acid process employing oxygen and nitric acid as co-oxidants is used to oxidize organic compounds subject to nitric acid oxidation, to their corresponding carboxylic acids. Oxidation of some carbohydrates by this process can produce one or more of their corresponding acid forms. The process is carried out at moderate temperatures, typically in the range of 20°C to 45 °C in a closed reactor, with oxygen gas being introduced into the reaction chamber as needed in order to sustain the reaction. Computer controlled reactors allow for careful and reproducible control of reaction parameters. Nitric acid can be recovered by a distillation / evaporation process, or by diffusion dialysis, the aqueous solution made basic with in...
|
| |
|
| 71. |
(WO 2008/020991) NOTARIZED FEDERATED IDENTITY MANAGEMENT
|
21.02.2008
|
H04K 1/00
|
PCT/US2007/017047
|
BROWN UNIVERSITY
|
| |
The exemplary embodiments of this invention provides notarized federated identity management that may have application like supporting efficient user authentication when providers are unknown to each other and/or for avoiding direct communication between identity providers and service providers, which provides improved privacy protection for users. In one non-limiting, exemplary embodiment, a method includes: receiving through a data communication network an assertion generated by a first entity; notarizing the assertion to obtain a corresponding notarized assertion; and in response to receiving from a second entity via the same or a different data communication; network a query corresponding to the assertion, returning the corresponding no...
|
| |
|
| 72. |
(WO 2008/020967) CATHETER AND ARRAY FOR ANTICANCER THERAPY
|
21.02.2008
|
A61M 5/00
|
PCT/US2007/016701
|
PEAK BIOSCIENCES, INC.
|
| |
A catheter array system adapted for implanting a plurality of catheters within the tissue of a patient in a spatially defined array, comprising a plurality of catheters, a catheter guide template adapted to guide the implantation of catheters, and a liquid supply system including a pressurizer and a manifold, is provided. A method of treatment of a malcondition in a patient comprises implantation of a spatially definted array of catheters using the system is also provided. The bioactive agent can be a radiotherapeutic agent, a chemotherapeutic agent, a protein, an antibody, an oligonucleotide-based therapeutic agent such as siRNA, or a combination of agents. A preferred radiotherapeutic agent is <sp>123</sp>I- or <s...
|
| |
|
| 73. |
(WO 2008/020962) CHOLESTEROL LOWERING DRUG COMBINATION
|
21.02.2008
|
A61K 31/397
|
PCT/US2007/016598
|
DUKE UNIVERSITY
|
| |
A patient with dyslipidemia is treated with a cholesterol blood level lowering effective amount of a non-statin cholesterol lowering agent and an amount of nitric oxide (NO) donating compound effective to mediate increase in nitric oxide bioactivity in blood.
|
| |
|
| 74. |
(WO 2008/020942) R-SPONDIN COMPOSITIONS AND METHODS OF USE THEREOF
|
21.02.2008
|
A61K 35/00
|
PCT/US2007/016197
|
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
|
| |
The invention provides for a method for screening compounds that bind to and modulate a regulator of Wnt signaling, R-spondin 4. The invention further provides for methods for diagnosing a keratin-related abnormality, such as anonychia congenital, in a subject. The invention also provides for isolated RSPO4 mutant molecules.
|
| |
|
| 75. |
(WO 2008/020934) MINIMAL-TEMPERATURE-DIFFERENTIAL, OMNI-DIRECTIONAL-REFLUX, HEAT EXCHANGER
|
21.02.2008
|
F28D 15/04
|
PCT/US2007/015805
|
UTAH STATE UNIVERSITY RESEARCH FOUNDATION
|
| |
A substrate (12) formed of a suitable conductive-heat-transfer material is formed with small channels (14) of a size selected to provide surface tension forces dominating a motion of a liquid-phase working fluid (40). A space above the channels (14) of the substrate (12) provides comparatively unobstructed space for the transport motion of a vapor phase (44) of the working fluid (40) effecting a heat-pipe effect in a multi-dimensional device. Channels (14) may typically be formed in an orthogonal grid providing capillary return of liquids (42) from a comparatively cooler condensation region to a comparatively warmer evaporation region, without any wicks other that the adhesion of the liquid phase working fluid (42) to the vertices of the ch...
|
| |
|
![[Back to Top]](/ipdl/include/backtop.gif){kind=small}
